Prothena is a biotechnology company engaged in the protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. Co. is developing a pipeline of therapeutic candidates for a number of indications and targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be utilized. Co.'s wholly-owned programs include birtamimab for the treatment of AL amyloidosis, a portfolio of programs for the treatment of Alzheimer's disease including PRX012 that targets Amyloid beta and a dual Amyloid beta-Tau vaccine.
Nothing in Metals Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and metals stock videos powered by Market News Video. Quote data delayed at least 20
minutes; data powered by Ticker Technologies, and Mergent. Contact Metals Channel; Meet Our Editorial Staff.